Sponsored by: Investment Center

Something new in your business?  Click here to submit your business press release

Chamber Corner | Main Street News | Job Hunt | Classifieds | Calendar | Illinois Lottery 

Eli Lilly 2Q profit jumps 16 pct on top drug sales

Send a link to a friend

[July 22, 2010]  INDIANAPOLIS (AP) -- Eli Lilly says its second-quarter net income soared 16 percent, boosted in part by strong sales growth from the drugmaker's top-selling drugs.

HardwareThe Indianapolis company says it earned $1.35 billion, or $1.22 per share, in the three months that ended June 30. That's up from $1.16 billion, or $1.06 per share, in the same period last year. Revenue rose 9 percent to $5.75 billion.

Excluding charges, net income was $1.24 per share.

Analyst polled by Thomson Reuters forecast earnings of $1.10 per share on $5.58 billion in revenue.

Sales for Lilly's best-selling drug, the antipsychotic Zyprexa, rose 5 percent, while revenue from its second-best seller, the antidepressant Cymbalta, climbed 17 percent.

[Associated Press]

Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Investments

Investments

< Recent articles

Back to top


 

News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries

Community | Perspectives | Law & Courts | Leisure Time | Spiritual Life | Health & Fitness | Teen Scene
Calendar | Letters to the Editor